November 30, 2015 (Shareholders Foundation) - An investigation on behalf of investors of XBiotech Inc (NASDAQ:XBIT) shares over potential securities laws violations by XBiotech Inc and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of XBiotech Inc (NASDAQ:XBIT) concerning whether a series of statements by XBiotech Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

XBiotech Inc began trading on April 15, 2015 and shares of XBiotech Inc (NASDAQ:XBIT) reached as high as $31.50 per share on April 20, 2015.

On November 23, 2015, XBiotech Inc (NASDAQ:XBIT) provided an update on the phase III oncology study in Europe. XBiotech Inc disclosed that data for 72 patients in its study of True Human(TM) therapeutic antibodies have been compromised and are not available for primary endpoint evaluation due to irregularities. XBiotech Inc said that these irregularities include patients dropping off the study prior to receiving any dosing with drug or placebo, erroneously receiving either placebo or study drug, and failing to receive scheduled DEXA scans, properly complete EORTC evaluation, or both.